Regulus Therapeutics (RGLS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -46,358 | -30,037 | -28,323 | -27,808 | -15,730 |
| Depreciation Amortization | -1,210 | 70 | -63 | 459 | 467 |
| Accounts payable and accrued liabilities | 743 | 29 | -110 | -250 | -786 |
| Other Working Capital | -1,882 | 257 | 550 | 914 | -41 |
| Other Operating Activity | 7,034 | 2,913 | 2,420 | 2,557 | 3,554 |
| Operating Cash Flow | $-41,673 | $-26,768 | $-25,526 | $-24,128 | $-12,536 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -35,643 | 15,101 | -14,759 | N/A | N/A |
| PPE Investments | -340 | -610 | -361 | -251 | N/A |
| Purchase Sale Intangibles | N/A | N/A | N/A | N/A | -11 |
| Other Investing Activity | 0 | 0 | 0 | 0 | -11 |
| Investing Cash Flow | $-35,983 | $14,491 | $-15,120 | $-251 | $-11 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | N/A | N/A | N/A | N/A | 662 |
| Debt Repayment | -1,377 | -3,304 | 0 | -80 | -10,277 |
| Common Stock Issued | 93,794 | 15,120 | 4,491 | 53,817 | 19,128 |
| Financing Cash Flow | $92,417 | $11,816 | $4,491 | $53,737 | $9,513 |
| Beginning Cash Position | 23,829 | 24,290 | 60,445 | 31,087 | 34,121 |
| End Cash Position | 38,590 | 23,829 | 24,290 | 60,445 | 31,087 |
| Net Cash Flow | $14,761 | $-461 | $-36,155 | $29,358 | $-3,034 |
| Free Cash Flow | |||||
| Operating Cash Flow | -41,673 | -26,768 | -25,526 | -24,128 | -12,536 |
| Capital Expenditure | -340 | -613 | -361 | -251 | N/A |
| Free Cash Flow | -42,013 | -27,381 | -25,887 | -24,379 | -12,536 |